Zota Health CareNSE:ZOTA +0.78%77 Days Payable is 160.10 as of Mar. 2026, which is 59% above its 10-year median of 100.72. GuruFocus rates NSE:ZOTA with a GF Score™ of 77/100 and a GF Value™ of ₹1,598.09 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 699 Biotechnology companies, Zota Health Care ranks better than 52.07% on this metric.
The historical rank and industry rank for Zota Health Care's Days Payable or its related term are showing as below:
NSE:ZOTA'
s Days Payable Range Over the Past 10 Years
Min: 70.08 Med: 100.72 Max: 125.38
Current: 119.12
During the past 13 years, Zota Health Care's highest Days Payable was 125.38. The lowest was 70.08. And the median was 100.72.
NSE:ZOTA's Days Payable is ranked better than 52.07% of 699
companies
in the Biotechnology industry
Industry Median: 112.84
vs NSE:ZOTA: 119.12
Zota Health Care's Days Payable
increased
from Mar. 2025 (80.82) to Mar. 2026 (160.10).
It may suggest that Zota Health Caredelayed paying its suppliers.
Zota Health Care Days Payable Related Terms
Zota Health Care Days Payable Historical Data
* Premium members only.
The historical data trend for Zota Health Care's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ZOTA vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Zota Health Care's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zota Health Care Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zota Health Care's Days Payable distribution charts can be found below:
* The bar in red indicates where Zota Health Care's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Zota Health Care's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zota Health Care (NSE:ZOTA) has a Days Payable of 160.10 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zota Health Care and its competitors. This is 59% above median its historical median of 100.72. Over the past decade, Zota Health Care's Days Payable has ranged from 70.08 to 125.38. According to the industry distribution chart, Zota Health Care ranks #335 out of 699 companies in the Biotechnology industry, placing it in the top 47.9%.
Is Zota Health Care's Days Payable too high?
Zota Health Care's current Days Payable of 160.10 is 59% above median its 10-year median of 100.72. Over the past 10 years, this metric has ranged from a low of 70.08 to a high of 125.38. The Biotechnology industry median Days Payable is 112.84. Zota Health Care's value of 160.10 is 41.9% above this industry median. Based on the distribution chart, Zota Health Care ranks #335 out of 699 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zota Health Care has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zota Health Care's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zota Health Care ranks #335 out of 699 companies for Days Payable. This puts Zota Health Care in the upper half of its industry. The industry median Days Payable is 112.84. Zota Health Care's value of 160.10 is 41.9% above this benchmark. Historically, Zota Health Care's own Days Payable has ranged from 70.08 to 125.38 over the past decade. While the company's 10-year median is 100.72 vs. the industry median of 112.84, Zota Health Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zota Health Care's current Days Payable of 160.10 is 41.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zota Health Care and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zota Health Care's current Days Payable is 160.10, which is 59% above median its own 10-year median of 100.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zota Health Care stock overvalued right now?
Based on GuruFocus' analysis, Zota Health Care (NSE:ZOTA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,598.09, compared to a current price of ₹1,412.70 — trading 11.6% below its estimated fair value. The current Days Payable is 160.10, which is 59% above median its 10-year median of 100.72 and 41.9% above the Biotechnology industry median of 112.84. Zota Health Care's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zota Health Care (NSE:ZOTA), the current Days Payable is 160.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zota Health Care (NSE:ZOTA) Overvalued in 2026?
Based on GuruFocus' analysis, Zota Health Care stock appears to be undervalued.
The current stock price of ₹1,412.70 is trading 11.6% below its estimated GF Value™ of ₹1,598.09.
GuruFocus considers Zota Health Care to be Modestly Undervalued.
Key valuation signals for NSE:ZOTA:
Days Payable: 160.10 (59% above median its 10-year median of 100.72)
GF Value™: ₹1,598.09 vs. price of ₹1,412.70 (11.6% below fair value)
Industry Position: 41.9% above the Biotechnology median (#335 of 699)
No single metric tells the full story. See the NSE:ZOTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zota Health Care Ltd is engaged in the manufacturing, trading, and export of pharmaceutical products. The company caters to both domestic and international markets. It offers a vast range of pharmaceutical, nutraceutical, ayurvedic, and OTC products in India and overseas as well.
77GF Score
Get the complete analysis for NSE:ZOTA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZOTA has been successfully added to your 
